A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan
Titel:
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan
Auteur:
Verschraegen, Claire F. Kudelka, Andrzej P. Hu, Wei Vincent, Monique Kayanagh, John J. Loyer, Evelyne Bastien, Luc Duggal, A. De Jager, R.